Director's substantial share purchase (27% increase in holdings) demonstrates insider confidence. Stock has outperformed S&P 500 by 21.3% over 12 months. Analyst consensus is strongly bullish with 89% buy ratings and median price target of $32 (31% upside potential). No sell ratings from analyst coverage.
Company beat Q1 earnings expectations (40 cents vs. 35 cents consensus), exceeded revenue guidance ($1.37B vs. $1.29B consensus), raised full-year earnings and sales guidance, demonstrated strong organic growth across both segments (Pet Health +12%, Farm Animal +18%), received emergency use authorizations for new products, and showed accelerating momentum into March and April with improved EBITDA margins.
Articles that tag ELAN but are mainly about other companies.
Listed as a leading market player with significant presence in the U.S. veterinary API manufacturing market, benefiting from strong domestic animal health spending and regulatory frameworks.
Company is highlighted as a global leader developing pharmaceuticals, vaccines, and wellness products for companion animals with focus on portfolio optimization, margin expansion, and new product innovation in growing pet therapeutics market.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
